



## Krystal Biotech to Present at Upcoming Investor Conferences

June 5, 2023

PITTSBURGH, June 05, 2023 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRY5) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the following upcoming investor conferences:

- William Blair 43<sup>rd</sup> Annual Growth Stock Conference: Krish S. Krishnan, Chairman and Chief Executive Officer, will present at 10:40 AM CT and host investor meetings on June 6, 2023 in Chicago, IL.
- Goldman Sachs 44<sup>th</sup> Annual Global Healthcare Conference: Krish S. Krishnan, Chairman and Chief Executive Officer, will present at 8:00 AM PT and host investor meetings on June 13, 2023 in Dana Point, CA.

A live webcast of the presentations can be accessed on the Investors section of the Company's [website](#) and an archived replay of each webcast will be available for approximately 30 days following the presentation.


### About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRY5) is a fully integrated R&D and commercial biotechnology company focused on genetic medicines for patients with rare diseases. The Company has in-house GMP manufacturing and a wide-ranging pipeline that is powered by its proprietary, redosable HSV-1 gene delivery platform. VYJUVEK™ is the Company's first commercial product and is the first-ever redosable gene therapy and the only medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. For more information, please visit <http://www.krystalbio.com>, and follow @KrystalBiotech on [LinkedIn](#) and [Twitter](#).

### CONTACT:

#### Investors and Media

Meg Dodge  
Krystal Biotech  
[mdodge@krystalbio.com](mailto:mdodge@krystalbio.com)



Source: Krystal Biotech, Inc.